争议FDA领导人维奈·普拉萨德将再次离开该机构。
Vinay Prasad, controversial FDA leader, to again depart agency
生物技术与制药领域的最新动态
Vinay Prasad, controversial FDA leader, to again depart agency
Servier to build cancer drug pipeline with $2.5B purchase of Day One
Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results
FDA issues speedy approval to J&J’s Tecvayli-Darzalex combo
Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
Lilly targets employers in new bid to broaden access to obesity drugs
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
A startup making drugs for blood disorders banks $160M
Moderna to pay up to $2.25B to end mRNA vaccine patent fight
Blackstone puts $400M into Teva, Sanofi gut disease drug
Prime to test FDA flexibility with 2-patient gene editing submission
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
Kyowa Kirin abandons touted eczema drug following safety review
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Ascendis wins FDA approval of dwarfism drug
UniQure says FDA wants another study of Huntington’s gene therapy
Roche pill succeeds in another MS study, but approval questions linger
Candid, in a reverse merger with RallyBio, to go public
Safety concerns spur Aardvark to halt key Prader-Willi drug trial
Why it’s critical to close open steps in cell therapy manufacturing